Friday the 13th has turned into a horror story for #Australianbiotech #Immutep, whose #shareprice collapsed after it abandoned a pivotal trial of its lead drug.

pharmaphorum.com/news/immutep...

#IMMP is tackling autoimmune diseases at the source. New Phase 1 data show 80% T cell suppression with no safety issues for its first-in-class LAG-3 agonist IMP761.
#Immutep
prismmarketview.com/early-data-f...